CCDC62 Variant rs12817488 Is associated with the risk of Parkinson's disease in a Han Chinese population

European Neurology

Volumn 71, Issue 1-2, 2014, Pages 77-83

  Liu, Rong Rong ^a   Zhou, Li Li ^a   Cheng, Xing ^a   Sun, Miao Xuan ^a   Hu, Yan Bing ^a   Chen, Song Fang ^a   Zhang, Xiong ^a   Zhu, Jian Hong ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

CCDC62; Genetic association; Parkinson's disease; PRDM2; rs12817488

Indexed keywords

ALLELE; ARTICLE; CAUCASIAN; CCDC62 GENE; CONTROLLED STUDY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAN CHINESE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; WESTERN BLOTTING;

AGE OF ONSET; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOTTING, WESTERN; CHINA; COHORT STUDIES; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GENOTYPING TECHNIQUES; HETEROZYGOTE; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; NUCLEAR PROTEINS; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; SEX FACTORS; TRANSCRIPTION FACTORS;

EID: 84894434973     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000354333     Document Type: Article

References (33)

1. Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP: Epidemiology of Parkinson's disease. J Neurol 2008; 255(suppl 5):18-32.
2. Gao J, Nalls MA, Shi M, et al: An exploratory analysis on gene-environment interactions for Parkinson disease. Neurobiol Aging 2012; 33: 2528e1-2528e6.
3. McCulloch CC, Kay DM, Factor SA, et al: Exploring gene-environment interactions in Parkinson's disease. Hum Genet 2008; 123: 257-265.
4. Wider C, Vilarino-Guell C, Heckman MG, et al: SNCA, MAPT, and GSK3B in Parkinson disease: a gene-gene interaction study. Eur J Neurol 2011; 18: 876-881.
5. Do CB, Tung JY, Dorfman E, et al: Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson's disease. PLoS Genet 2011; 7:e1002141.
6. Lill CM, Roehr JT, McQueen MB, et al: Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. PLoS Genet 2012; 8:e1002548.
7. International Parkinson's Disease Genomics Consortium (IPDGC), Wellcome Trust Case Control Consortium 2 (WTCCC2): A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet 2011; 7:e1002142.
8. Nalls MA, Plagnol V, Hernandez DG, et al: Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genomewide association studies. Lancet 2011; 377: 641-649.
9. Sharma M, Ioannidis JP, Aasly JO, et al: Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology 2012; 79: 659-667.
10. Pihlstrom L, Axelsson G, Bjornara KA, et al: Supportive evidence for 11 loci from genomewide association studies in Parkinson's disease. Neurobiol Aging 2012; 34: 1708e7-1708.e13.
11. Chen M, Ni J, Chang HC, Lin CY, Muyan M, Yeh S: CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor betamediated transactivation and target gene expression in prostate cancer cells. Carcinogenesis 2009; 30: 841-850.
12. Chen M, Ni J, Zhang Y, Muyan M, Yeh S: ERAP75 functions as a coactivator to enhance estrogen receptor alpha transactivation in prostate stromal cells. Prostate 2008; 68: 1273-1282.
13. Westberg L, Hakansson A, Melke J, et al: Association between the estrogen receptor beta gene and age of onset of Parkinson's disease. Psychoneuroendocrinology 2004; 29: 993-998.
14. Hakansson A, Westberg L, Nilsson S, et al: Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2005; 133B:88-92.
15. Dluzen DE, McDermott JL, Liu B: Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol Teratol 1996; 18: 603-606.
16. Leranth C, Roth RH, Elsworth JD, Naftolin F, Horvath TL, Redmond DE Jr: Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. J Neurosci 2000; 20: 8604-8609.
17. Chung SJ, Armasu SM, Biernacka JM, et al: Variants in estrogen-related genes and risk of Parkinson's disease. Mov Disord 2011; 26: 1234-1242.
18. Dluzen D: Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res 1997; 767: 340-344.
19. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
20. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ: A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009; 132: 2947-2957.
21. Zhu JH, Chen CL, Flavahan S, Harr J, Su B, Flavahan NA: Cyclic stretch stimulates vascular smooth muscle cell alignment by redoxdependent activation of Notch3. Am J Physiol Heart Circ Physiol 2011; 300:H1770-H1780.
22. Elbaz A, Bower JH, Maraganore DM, et al: Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol 2002; 55: 25-31.
23. Rocca WA, Bower JH, Maraganore DM, et al: Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008; 70: 200-209.
24. Benedetti MD, Maraganore DM, Bower JH, et al: Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord 2001; 16: 830-837.
25. Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S: The effect of estrogen replacement on early Parkinson's disease. Neurology 1999; 52: 1417-1421.
26. Wang L, Andersson S, Warner M, Gustafsson JA: Morphological abnormalities in the brains of estrogen receptor beta knockout mice. Proc Natl Acad Sci USA 2001; 98: 2792-2796.
27. D'Astous M, Morissette M, Di Paolo T: Effect of estrogen receptor agonists treatment in MPTP mice: evidence of neuroprotection by an ER alpha agonist. Neuropharmacology 2004; 47: 1180-1188.
28. Bourque M, Morissette M, Cote M, Soulet D, Di Paolo T: Implication of GPER1 in neuroprotection in a mouse model of Parkinson's disease. Neurobiol Aging 2013; 34: 887-901.
29. Al-Sweidi S, Morissette M, Bourque M, Di Paolo T: Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson's disease. Neuropharmacology 2011; 61: 583-591.
30. Kim S, Jeon BS, Heo C, et al: Alpha-synuclein induces apoptosis by altered expression in human peripheral lymphocyte in Parkinson's disease. FASEB J 2004; 18: 1615-1617.
31. Thevenet J, Pescini Gobert R, Hooft van Huijsduijnen R, Wiessner C, Sagot YJ: Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS One 2011; 6:e21519.
32. Ullrich C, Mlekusch R, Kuschnig A, Marksteiner J, Humpel C: Ubiquitin enzymes, ubiquitin and proteasome activity in blood mononuclear cells of MCI, Alzheimer and Parkinson patients. Curr Alzheimer Res 2010; 7: 549-555.
33. Mata IF, Shi M, Agarwal P, et al: SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol 2010; 67: 1350-1356.